The terminal complement inhibitor eculizumab reduces thrombosis in patients with paroxysmal nocturnal hemoglobinuria.

被引：0
|
作者：
Hillmen, Peter
Muus, Petra
Duehrsen, Ulrich
Risitano, Antonio M.
Schubert, Joerg
Young, Neal S.
Schrezenmeier, Hubert
Szer, Jeffrey
Brodsky, Robert A.
Hill, Anita
Socie, Gerard
Rollins, Scott A.
Rother, Russell P.
Bell, Leonard
Luzzatto, Lucio
机构：
[1] Leeds Gen Infirm, Leeds, W Yorkshire, England
[2] Radboud Univ Nijmegen, Nijmegen, Netherlands
[3] Univ Hosp, Sch Med, Essen, Germany
[4] Mediche Federico Univ 2, NIH, Naples, Italy
[5] Saarland Univ, Homburg, Germany
[6] NHLBI, Bethesda, MD USA
[7] Inst Clin Transfusionmedizi & Immungenetikn, Helmholtzstr, Germany
[8] Royal Hosp, INSERM, Melbourne, Vic, Australia
[9] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[10] Hop St Louis, Paris, France
[11] Alexion Pharmaceut Inc, Cheshire, CT USA
[12] Ins Toscano Tumori, Florence, Italy
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
123
引用
收藏
页码：40A / 41A
页数：2
相关论文
共 50 条
  • [41] Thrombosis in Patients with Paroxysmal Nocturnal Hemoglobinuria
    Weitz, Ilene C.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2011, 37 (03): : 315 - 321
  • [42] KINETIC PARAMETERS OF COMPLEMENT ACTIVATION IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DURING ECULIZUMAB THERAPY
    Tarasova, Yu, V
    Klimova, O. U.
    Andreeva, L. A.
    Vasina, L. V.
    Galebskaya, L., V
    Babenko, E., V
    Kulagin, A. D.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2020, 65 (02): : 126 - 137
  • [43] Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment
    Subias Hidalgo, Marta
    Martin Merinero, Hector
    Lopez, Alicia
    Anter, Jaouad
    Pinto Garcia, Sheila
    Ataulfo Gonzalez-Fernandez, Fernando
    Fores, Rafael
    Lopez-Trascasa, Margarita
    Villegas, Ana
    Ojeda, Emilio
    Rodriguez de Cordoba, Santiago
    IMMUNOBIOLOGY, 2017, 222 (02) : 363 - 371
  • [44] The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria
    Kulasekararaj, Austin G.
    Brodsky, Robert A.
    Nishimura, Jun-ichi
    Patriquin, Christopher J.
    Schrezenmeier, Hubert
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [45] Mechanisms of resistance to apoptosis in granulocytes of patients with paroxysmal nocturnal hemoglobinuria.
    Moody, MA
    Howard, TA
    Ware, RE
    BLOOD, 1998, 92 (10) : 6B - 7B
  • [46] Survival benefit of eculizumab in patients with paroxysmal nocturnal hemoglobinuria
    Patel, Ami
    Metzger, Jesse
    Terriou, Louis
    Patriquin, Christopher
    Griffin, Morag
    Lee, Jong Wook
    Gustovic, Phillippe
    Jiang, Wei
    Szer, Jeff
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 264 - 265
  • [47] Eculizumab in the Treatment of Paroxysmal Nocturnal Hemoglobinuria
    Hill, Anita
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1467 - 1476
  • [48] Eculizumab (Soliris) for paroxysmal nocturnal hemoglobinuria
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2007, 49 (1270): : 79 - 80
  • [49] A CASE OF CHILDHOOD PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA: SAFETY AND EFFICACY OF THE TERMINAL COMPLEMENT INHIBITOR ECULIZUMAB
    La Barba, G.
    Sau, A.
    Pulini, S.
    Passeri, C.
    Salutari, P.
    Melatti, G.
    Risitano, A. M.
    Fioritoni, G.
    HAEMATOLOGICA, 2008, 93 : S60 - S60
  • [50] Paroxysmal Nocturnal Hemoglobinuria With Budd-Chiari Syndrome Treated With Complement Inhibitor Eculizumab; A Case Report
    Valeri, Federica
    Borchiellini, Alessandra
    Schinco, Piercarla
    Boccadoro, Mario
    BLOOD, 2013, 122 (21)
12345